Know Cancer

forgot password

Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer

Phase 2
18 Years
Not Enrolling
Gastric Cancer

Thank you

Trial Information

Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer

All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each
cycle). Efficacy will be evaluated every 3 cycles.

Inclusion Criteria:

- Age of 18years or over

- Patients who had failed more than 1 cycle of standard therapy with advanced or
metasatic stage and with measurable lesions

- Life expectancy >/= 5 months

- Not available to any of resectable surgery or radiotherapy

- Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as
defined by

1. Absolute neutrophil count(ANC)>/= 1.0 x 10^9/L, Platelet count >/= 75 x 10^9/L

2. Total bilirubin < 2.0mg/dL

3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) < 5 x Upper
Limit Normal(ULN)

4. creatinine < 2 x ULN

- ECOG status 0 to 2

- Female volunteers admitted to the study must be using a reliable means of
contraception and must have a negative blood or urine pregnancy test at least 7days

- Patients or their legal representatives who have signed the informed consent form.

Exclusion Criteria:

- Known brain or spinal cord metastases

- Patients who have received chemotherapy within the previous 4 weeks

- Patients who have received radiotherapy related tp Gastric cancer within 4weeks

- Patients who have participated in other clinical study within the previous 4weeks

- Pregnancy (absence to be confirmed by ß-hCG test) or lactation period

- Human immunodeficiency virus(HIV) antibody (+)

- Have active infection or serious concomitant systemic disorder incompatible with the

- Clinically hypertension or diabete mellitus not well controlled with medication

- Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic
coronary artery disease and cardiac arrhythmias) or myocardial infarction

- Presence or history of malignancy other than Gastirc cancer within 5years

- Have severe Neurologic or psychological disorder

- Patients who have history of allery with this investigational drug(SB injection)

- Obvious cognitive or physical impairment that would prevent participation

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluating Tumor Response Rate

Outcome Time Frame:

4 months

Safety Issue:


Principal Investigator

Yong-oon Shin, Prof

Investigator Role:

Principal Investigator

Investigator Affiliation:

Inha University Hospital


Korea: Food and Drug Administration

Study ID:

SB injection-G002



Start Date:

May 2011

Completion Date:

Related Keywords:

  • Gastric Cancer
  • Stomach Neoplasms